Exposure of patients with myofascial pain syndrome (MPS) to capsaicin : development of pharmaceutical form for topical use with possible analgesic action

Author(s)

Valeria Romero Vieira da Motta

• Document type: Doctoral Thesis
• Press: Botucatu. 2016-06-07.
• Institution: Universidade Estadual Paulista (Unesp). Faculdade de Medicina. Botucatu
• Defense date: 2015-02-09
• Advisor: Guilherme Antonio Moreira de Barros

Abstract

Background and Objective: myofascial pain syndrome (MPS) is one of the most common causes of musculoskeletal pain. This pain may originate in a single muscle and eventually may involve multiple muscles generating complex patterns and variable painful symptoms. In this study capsaicin, a natural product obtained from red pepper, was formulated in a high concentration. Capsaicin, which has long been used for the management of pain, was tested as an alternative to the management of the MPS. The objective of this study was to develop and evaluate the potential analgesic action of a semi-solid formulation (cream) containing capsaicin 8% on myofascial pain syndrome patients. At the same time we evaluated the occurrence of cutaneous side effects related to the topic use of capsaicin, as well as the plasma capsaicin concentrations result of its use. Also the residual capsaicin concentration was tested in the formulations after 10 months of manufacturing. Methods: two formulations were developed: Fc1 (based cream formula) and Fc2 (cream formula base + capsaicin 8%). The formulations were submitted to microbiological tests, physical and chemical quality evaluation, as recommended by ANVISA. This prospective, randomized study was conducted in Pain Management and Palliative Care Service (TACP), Botucatu, Botucatu Medical School, UNESP. The 40 participating patients were assigned into two groups, Fc1 and Fc2. The clinical tests were carried out at the hospital; the creams were administered topically, as per assigned group, with the prior use of topical local anesthetic for 50 minutes. The trigger point (PG) that aroused more discomfort and pain on palpation was chosen for topical application of the formulations (10 g) in an enclosed area of about 24 mm and above this point. After 30 minutes the product was removed and parameters of the skin tolerability were evaluated. The pain was measured immediately before and during application of the ... (AU)

• FAPESP's process: 12/22294-3 - Exposure of patients with myofascial pain syndrome to capsaicin: development of topical dosage form with possible analgesic
• Grantee: Valeria Romero Vieira da Motta
• Support Opportunities: Scholarships in Brazil - Doctorate